Skip to main content
. 2018 Jan 24;24:461–472. doi: 10.12659/MSM.908430

Figure 4.

Figure 4

Curcumol decreases CSLCs self-renewal and DNMT/HDAC activity in vitro. (A) Chemical structure of curcumol. (B) IC50 dose response curves of JEG-3 cells with different doses curcumol at 24 h and 48 h. (C) Representative tumorospheres images (10×) of DMSO and treated 75 μg/ml curcumol for 7 days (left) and sphere counts in first- and second-generation in cells (right). (D) Flow cytometry analysis of CD133 cell surface expression in sphere cells with curcumol treatment. (E) RT-PCR analysis of NANOG, OCT4, SOX2, and ABCG2 mRNA expression levels in sphere cells with curcumol treatment. (F) Quantification of 5-mC in sphere cells with curcumol treatment. (G) Western blot analysis of DNMT1/3b and HDAC1/3 in sphere cells with RA treatment. GAPDH was used as the internal control (left). Respective changes in DNMTs and HDACs (right) protein levels. (H) The mRNA expression levels of DNMT1/3b and HDAC1/3 in cells with curcumol treatment. (I) After curcumol treatment, HDAC activity was detected. Data represent mean ±SD from at least 3 independent experiments, * p<0.05; ** p<0.01; *** p<0.001.